Equities Analysts Offer Predictions for COLL Q2 Earnings

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Equities research analysts at HC Wainwright dropped their Q2 2026 earnings per share (EPS) estimates for Collegium Pharmaceutical in a research note issued on Thursday, April 23rd. HC Wainwright analyst B. Folkes now anticipates that the specialty pharmaceutical company will post earnings of $1.48 per share for the quarter, down from their prior estimate of $1.65. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $6.51 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical’s Q4 2026 earnings at $2.14 EPS and FY2026 earnings at $6.27 EPS.

COLL has been the topic of a number of other research reports. Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Needham & Company LLC reiterated a “buy” rating and set a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. Weiss Ratings cut Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. Barclays cut their target price on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a research report on Friday, January 9th. Finally, Wall Street Zen lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $53.40.

Collegium Pharmaceutical Stock Down 2.4%

COLL opened at $32.28 on Friday. The business’s 50-day simple moving average is $37.07 and its 200-day simple moving average is $41.41. The company has a debt-to-equity ratio of 2.59, a quick ratio of 1.48 and a current ratio of 1.57. Collegium Pharmaceutical has a one year low of $25.98 and a one year high of $50.79. The stock has a market capitalization of $1.05 billion, a P/E ratio of 18.88 and a beta of 0.77.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). Collegium Pharmaceutical had a return on equity of 98.65% and a net margin of 8.05%.The firm had revenue of $205.45 million for the quarter, compared to analyst estimates of $206.36 million. During the same quarter last year, the firm posted $1.77 EPS. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in the stock. Illinois Municipal Retirement Fund increased its position in Collegium Pharmaceutical by 1.6% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 17,281 shares of the specialty pharmaceutical company’s stock valued at $605,000 after acquiring an additional 278 shares during the period. Vident Advisory LLC boosted its holdings in Collegium Pharmaceutical by 1.9% in the 3rd quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock valued at $541,000 after purchasing an additional 281 shares in the last quarter. Quadrant Capital Group LLC boosted its holdings in Collegium Pharmaceutical by 4.2% in the 4th quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock valued at $324,000 after purchasing an additional 282 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Collegium Pharmaceutical by 9.6% in the 4th quarter. GAMMA Investing LLC now owns 3,262 shares of the specialty pharmaceutical company’s stock valued at $151,000 after purchasing an additional 285 shares in the last quarter. Finally, Atom Investors LP boosted its holdings in Collegium Pharmaceutical by 5.0% in the 4th quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock valued at $284,000 after purchasing an additional 294 shares in the last quarter.

Insider Activity

In related news, EVP David Dieter sold 13,976 shares of the business’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total value of $488,041.92. Following the transaction, the executive vice president owned 77,071 shares in the company, valued at $2,691,319.32. The trade was a 15.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Scott Dreyer sold 49,976 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total value of $2,019,530.16. Following the completion of the transaction, the executive vice president owned 71,770 shares in the company, valued at $2,900,225.70. This trade represents a 41.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.85% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.